LL37 5MG

LL-37 (5mg) — Quick Overview

What it is: A naturally occurring human antimicrobial peptide (part of the cathelicidin family), produced by immune cells (neutrophils, macrophages) and epithelial cells as part of innate immune defense. The synthetic version sold as “LL-37 5mg” is a lab-made copy of this natural peptide, marketed in the research-chemical/peptide space.

Mechanism of action:

• LL-37 has a positively charged, amphipathic structure that lets it insert into and disrupt negatively charged bacterial cell membranes, giving it direct antimicrobial activity against bacteria, some fungi, and enveloped viruses

• Beyond killing microbes directly, it acts as an immune signaling molecule — recruiting immune cells, promoting wound healing, and modulating inflammation

• It’s also been studied for a role in angiogenesis (new blood vessel formation) and tissue repair

Studied contexts:

• Innate immunity and infection defense (its primary natural role)

• Wound healing research

• Chronic inflammatory skin conditions (interestingly, LL-37 is a double-edged sword here — it’s protective at normal levels but overexpression is linked to autoimmune skin conditions like psoriasis and rosacea)

• Early-stage cancer research exploring both pro- and anti-tumor effects depending on context

Evidence status: Reasonably well-studied at the basic science level (hundreds of peer-reviewed papers on mechanism and cell/animal studies), but there are no approved human drug formulations or clinical dosing guidelines for therapeutic injection use.

Regulatory status:

• Not FDA-approved as a drug product in any injectable form

• Sold almost exclusively through research-chemical/peptide vendors, not pharmacies

• No standardized human safety data for the doses and delivery methods (e.g., injection) being marketed — its natural role is as a locally-acting peptide the body produces itself, not something historically given systemically